Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 1001 - 1100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1001 | 25001309 |
US |
53 | 1 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 1002 | 25001366 |
US |
44 | 2 |
Injection site bruising, Injection site pain, Accidental exposure to product, Drug dose omission by device, Device difficult to use, Incorrect dose administered by device, |
||||
ERENUMAB-AOOE, |
||||
| 1003 | 25001393 |
US |
77 | 2 |
Injection site pain, Skin exfoliation, Pruritus, Drug dose omission by device, Device defective, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 1004 | 24997384 |
US |
68 | 2 |
Eye operation, Device difficult to use, Accidental exposure to product, |
||||
ETANERCEPT, |
||||
| 1005 | 24997757 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1006 | 24997830 |
US |
2 | |
Injection site urticaria, Device leakage, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1007 | 24997859 |
US |
79 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1008 | 24997896 |
US |
54 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1009 | 24997899 |
US |
10 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1010 | 24997905 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 1011 | 24997922 |
US |
6 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1012 | 24997987 |
US |
60 | 2 |
Injection site pain, Injection site swelling, Injection site erythema, Injection site pruritus, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1013 | 24998045 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1014 | 24998050 |
US |
36 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1015 | 24998072 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1016 | 24998104 |
US |
31 | 2 |
Injection site erythema, Injection site pruritus, Injection site swelling, Injection site bruising, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1017 | 24998109 |
US |
8 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1018 | 24998112 |
US |
23 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1019 | 24998138 |
US |
59 | 2 |
Injection site urticaria, Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, Injection site pain, Injection site swelling, Injection site bruising, |
||||
DUPILUMAB, |
||||
| 1020 | 24998217 |
US |
||
Injection site mass, Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1021 | 24998243 |
US |
69 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 1022 | 24998269 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1023 | 24998277 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1024 | 24998283 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1025 | 24998293 |
US |
35 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1026 | 24998300 |
US |
2 | |
Rash, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1027 | 24998361 |
US |
79 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 1028 | 24998369 |
US |
60 | 1 |
Injection site urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1029 | 24998400 |
US |
53 | 2 |
Product use in unapproved indication, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1030 | 24998407 |
US |
68 | 1 |
Burning sensation, Eczema, Inappropriate schedule of product administration, Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ERGOCALCIFEROL, FEXOFENADINE HYDROCHLORIDE, ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, PRAVASTATIN SODIUM, AMLODIPINE BESYLATE, VALSARTAN, TIRZEPATIDE, |
||||
| 1031 | 24998415 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1032 | 24998457 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1033 | 24998473 |
US |
78 | 2 |
Rebound atopic dermatitis, Rash, Product dose omission issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1034 | 24998480 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1035 | 24998487 |
US |
48 | 2 |
Accidental exposure to product, Exposure via skin contact, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1036 | 24998491 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1037 | 24998531 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1038 | 24998546 |
US |
49 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1039 | 24998610 |
US |
65 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1040 | 24998612 |
US |
82 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1041 | 24998630 |
US |
78 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1042 | 24998672 |
US |
12 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1043 | 24998718 |
US |
4 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1044 | 24998763 |
US |
51 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1045 | 24998790 |
US |
2 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1046 | 24998807 |
US |
62 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1047 | 24998836 |
US |
58 | 2 |
Influenza, Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 1048 | 24998854 |
US |
21 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 1049 | 24998867 |
US |
38 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1050 | 24998960 |
US |
52 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1051 | 24999000 |
US |
8 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1052 | 24999012 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1053 | 24999028 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1054 | 24999050 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 1055 | 24999062 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1056 | 24999065 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1057 | 24999095 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 1058 | 24999137 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 1059 | 24999138 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1060 | 24999140 |
US |
23 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1061 | 24999182 |
US |
69 | 2 |
Intentional dose omission, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 1062 | 24999228 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1063 | 24999261 |
US |
4 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1064 | 24999280 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1065 | 24999301 |
US |
2 | |
Ocular discomfort, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1066 | 24999307 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1067 | 24999353 |
US |
15 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1068 | 24999379 |
US |
49 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1069 | 24999399 |
US |
51 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1070 | 24999425 |
US |
28 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1071 | 24999427 |
US |
74 | 1 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1072 | 24999488 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1073 | 24999491 |
US |
49 | 2 |
Injection site pain, Injection site bruising, Injection site erythema, Accidental exposure to product, Exposure via skin contact, Intentional product misuse, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1074 | 24999538 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1075 | 24999548 |
US |
74 | 2 |
Injection site discharge, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1076 | 24999647 |
US |
71 | 2 |
COVID-19, Road traffic accident, Pain in extremity, Accidental exposure to product, Exposure via skin contact, Off label use, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, ROFLUMILAST, RALOXIFENE, QUETIAPINE FUMARATE, QUETIAPINE, MONTELUKAST SODIUM, MONTELUKAST, LORATADINE, LORATADINE ORAL, IRON, GABAPENTIN, FLUTICASONE PROPIONATE, FISH OIL, FAMOTIDINE, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, ALBUTEROL SULFATE, ALPRAZOLAM, |
||||
| 1077 | 24999694 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1078 | 24999697 |
US |
30 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1079 | 24999700 |
US |
80 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1080 | 24999704 |
US |
11 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1081 | 24999737 |
US |
87 | 2 |
Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 1082 | 24999800 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1083 | 24999865 |
US |
77 | 1 |
Injection site haemorrhage, Incorrect dose administered by product, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1084 | 24999944 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1085 | 24999980 |
US |
21 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1086 | 25000027 |
US |
60 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1087 | 25000044 |
US |
1 | |
Visual impairment, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 1088 | 25000072 |
US |
26 | 2 |
Accidental exposure to product, Exposure via skin contact, Product storage error, |
||||
DUPILUMAB, |
||||
| 1089 | 25000075 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1090 | 25000088 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1091 | 25000108 |
US |
83 | 1 |
Lacrimation increased, Eye pruritus, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 1092 | 25000131 |
US |
36 | 2 |
Arthralgia, Injection site pain, Exposure via skin contact, Accidental exposure to product, Off label use, |
||||
DUPILUMAB, |
||||
| 1093 | 25000152 |
US |
35 | 2 |
Injection site pain, Product preparation error, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 1094 | 25000203 |
US |
2 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1095 | 25000212 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1096 | 25000252 |
US |
70 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1097 | 25000305 |
US |
2 | |
Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 1098 | 25000331 |
US |
53 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1099 | 25000378 |
US |
75 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 1100 | 25000428 |
US |
75 | 2 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28